Barbara Pro

2K posts

Barbara Pro banner
Barbara Pro

Barbara Pro

@bpromd

Lymphoma Doc @columbiacancer @nyphospital Tweets are my own

Присоединился Nisan 2014
411 Подписки1.9K Подписчики
Закреплённый твит
Barbara Pro
Barbara Pro@bpromd·
Some personal news….after 6 great years @LurieCancer I joined @columbiacancer as director of the lymphoma program. I am thrilled to be working with an exceptional group of clinical reasearchers and scientists to advance the understanding and treatment of lymphoma. #lymsm
Manhattan, NY 🇺🇸 English
56
15
261
0
Barbara Pro ретвитнул
Blood Journals Portfolio
Blood Journals Portfolio@BloodPortfolio·
We're delighted to welcome Dr. Jennifer Amengual as a new Associate Editor for Blood Neoplasia! Dr. Amengual is an Associate Professor of Medicine at @columbiamed and a physician-scientist whose research focuses on developing targeted therapies for patients with lymphoma.
Blood Journals Portfolio tweet media
English
0
1
1
1.5K
Barbara Pro ретвитнул
Multiple Myeloma Hub
Multiple Myeloma Hub@MM_Hub·
CONGRESS | #SOHO2025 | PRESENTATION Suzanne Lentzsch @SLentzsch @columbiacancer discussed novel approaches and therapies for the treatment of #amyloidosis. A dFLC <10mg/L is associated with the best outcomes, SoC therapy is Dara-VCd for all patients, and venetoclax for patients with t(11;14). Future directions may include BCMA-directed ADCs, BiTEs, and CAR T. Follow our live feed for more updates: loom.ly/A5nL2WA #myeloma #mmsm #MultipleMyeloma
Multiple Myeloma Hub tweet mediaMultiple Myeloma Hub tweet mediaMultiple Myeloma Hub tweet mediaMultiple Myeloma Hub tweet media
English
0
4
15
1.1K
Barbara Pro ретвитнул
DAVA Oncology
DAVA Oncology@DAVAOnc·
ILC is biologically distinct yet often treated like IBC-NST. Dr. Massimo Cristofanilli (@WeillCornell) shows genomic/transcriptomic profiling reveals enrichment in actionable mutations (PIK3CA, ERBB2) & unique PAM50 subtypes #DAVABreast
DAVA Oncology tweet mediaDAVA Oncology tweet mediaDAVA Oncology tweet media
English
0
1
3
416
Barbara Pro ретвитнул
PER
PER@gotoPER·
The Big Apple brought big insights this weekend at #MXH25 🍎🩸 The energy was electric, the debates were sharp, and the NYC vibes were unmatched. See you next year for more insights and more Medical Crossfire. 🔥 tinyurl.com/6nv7s9cr #gotoPER @Dr_AmerZeidan @szusmani @bpromd
PER tweet mediaPER tweet mediaPER tweet mediaPER tweet media
English
1
3
9
2K
Barbara Pro ретвитнул
Michael Hughes
Michael Hughes@MSHughes_MD·
Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by @SLentzsch! #ASCO25 #MYELOMA #MRD @columbiacancer
Michael Hughes tweet media
English
0
4
10
1.1K
Barbara Pro ретвитнул
Gareth Morgan
Gareth Morgan@DrGarethMorgan1·
Suzanne Lentzsch receives the CoMy award for women’s achievement in MM very deserved and supported by her family and work colleagues
Gareth Morgan tweet media
English
4
7
42
3.7K
Barbara Pro ретвитнул
PER
PER@gotoPER·
Start spreadin’ the news… we’re headed to New York for the 9th Annual Live Medical Crossfire®: Hematologic Malignancies! Join @bpromd @szusmani @Dr_AmerZeidan for expert-led debates and real-time insights! 🗽Get 75% off HCP registration with code MXH75 bit.ly/4jIw2wE
PER tweet media
English
0
4
5
2.1K
Jaehyuk Choi
Jaehyuk Choi@jaehyukchoimd·
Excited to announce my next chapter: I'm joining @UTSWNews as the inaugural Director of the Center for Cellular Therapies and Cancer Immunology! Looking forward to building innovative #immunotherapy programs and advancing #cancerresearch with the outstanding team at UTSW. #1/3
English
57
20
252
27K
Barbara Pro ретвитнул
Hua-Jay (Jeff) Cherng
Hua-Jay (Jeff) Cherng@hjcherng·
🩸🧬Happy to share this @ForesightDx release ahead of #ASH24 on our MRD-guided study for newly diagnosed DLBCL is now open at @columbiacancer! The overall goal is to de-escalate cytotoxic chemotherapy for early molecular responders #lymsm #mrd clinicaltrials.gov/study/NCT06693…
Hua-Jay (Jeff) Cherng tweet media
Foresight Diagnostics Inc.@ForesightDx

We are pleased to share that our Foresight CLARITY #MRD test will be used in @ColumbiaMed's SHORTEN-ctDNA trial, which aims to evaluate the ability to utilize MRD detection to enable real-time treatment optimization for patients with #DLBCL. hubs.li/Q02-y31N0

English
1
8
26
4.2K

Открыть

@ColumbiaMed @Bloodneoplasia @BloodPortfolio @ASH_hematology @ev_lando @patrickwgould @hjcherng @columbiacancer